Amarin Corporation plc (AMRN) Investor Relations Documents

Amarin Corporation plc (AMRN) investor relations documents from the company's IR site: 2 presentations, 38 press releases; latest deck 2026-07-28. Read in-app with summaries. First-party data.

Amarin Corporate Overview Presentation: Amarin is a cardiovascular therapeutics company focused on VASCEPA/VAZKEPA, reporting Q2 2026 results with $39.1M in revenue and a shift to a leaner operating model.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-28Press releasePress release
2026-08-28Press releaseNew REDUCE-IT® Legacy Analysis Presented at European Society of Cardiology (ESC) Congress 2026 Suggests Persistent Cardi
2026-08-24Press releasePress release
2026-08-24Press releaseNew Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congre
2026-07-29Press releasePress release
2026-07-29Press releaseAmarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commer
2026-07-29Press releaseRead More
2026-07-29Press releasePress release
2026-07-28PresentationAmarin Corporate Overview Presentation
2026-07-15Press releasePress release
2026-07-15Press releaseAmarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026
2026-07-15Press releaseRead More
2026-06-30Press releasePress release
2026-06-30Press releaseAmarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatm
2026-05-27Press releasePress release
2026-05-27Press releasePress release
2026-05-27Press releaseNew REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted Apo
2026-04-29Press releasePress Release
2026-04-29PresentationAmarin Corporate Overview
2026-04-29Press releasePress release
2026-04-29Press releaseAmarin Reports 2026 First Quarter Financial Results
2026-04-15Press releasePress release
2026-04-15Press releaseAmarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026
2026-04-15Press releaseAmarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29...
2026-04-08Press releasePress release
2026-04-08Press releaseAmerican College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including
2026-04-08Press releasehttps://investors.amarincorp.com/node/25316/pdf
2026-03-18Press releasePress release
2026-03-18Press releaseAmarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Upd
2026-03-18Press releasehttps://investors.amarincorp.com/node/25286/pdf
2026-03-16Press releasePress release
2026-03-16Press releaseNew REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosa
2026-03-16Press releasehttps://investors.amarincorp.com/node/25276/pdf
2026-03-02Press releasePress release
2026-03-02Press releaseEffects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published
2026-03-02Press releasehttps://investors.amarincorp.com/node/25261/pdf
2026-02-25Press releasePress release
2026-02-25Press releaseAmarin Reports Fourth Quarter and Full Year 2025 Financial Results
2026-02-25Press releasePress release
2026-02-25Press releasehttps://investors.amarincorp.com/node/25246/pdf

AMRN overview · AMRN earnings · AMRN financials · AMRN KPIs · AMRN documents · AMRN ownership · AMRN peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.